Premium
Challenging patient populations in breast cancer: Taxane resistance and triple‐negative receptor subtype
Author(s) -
OHNO Shinji,
FORNIER Monica N
Publication year - 2008
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2008.00193.x
Subject(s) - taxane , triple negative breast cancer , oncology , breast cancer , medicine , estrogen receptor , disease , cancer
Over the last decade the introduction of the taxanes and several targeted therapies have led to an improvement in breast cancer morbidity and mortality. However, several groups of patients, including patients with taxane‐resistant, multidrug resistant, and estrogen‐negative, progesterone‐negative, and HER2/neu receptor‐negative tumors, have now emerged that present challenges to clinicians as they strive to improve the outcomes for patients with breast cancer. This review examines the state of knowledge at the time of writing regarding the mechanisms of taxane resistance and the natural history of triple‐negative disease. Strategies for overcoming taxane resistance and the improving clinical outcomes for these groups of patient are discussed.